ALX Oncology Holdings Inc. announced fourth quarter and full-year 2025 financial results, reporting a significant reduction in net losses compared to prior periods. The biopharmaceutical company simultaneously disclosed meaningful progress across its clinical development portfolio, highlighted by the validation of CD47 as a predictive biomarker for patient response to its lead therapeutic candidate evorpacept in ongoing cancer trials.
To strengthen its financial position, ALX Oncology completed a $150 million equity offering that extends the company's cash runway into the first half of 2028, providing visibility for sustained clinical development activities. The company also announced the appointment of Barbara Klencke as permanent Chief Medical Officer, filling a key leadership position within the organization. These developments underscore management's confidence in the clinical value of its pipeline while ensuring adequate capital resources for upcoming development activities.
Looking ahead, ALX Oncology anticipates multiple clinical milestones from its lead programs, including evorpacept and ALX2004, over the next 12 to 18 months. These data readouts are expected to further inform the clinical potential of the company's CD47-targeting approach in various cancer indications. The convergence of strengthened finances, clinical validation of biomarker-driven selection strategies, and anticipated trial progression positions the company to advance its development agenda through critical inflection points.